Comparative Pharmacology
Head-to-head clinical analysis: PLENDIL versus SULAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLENDIL versus SULAR.
PLENDIL vs SULAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Nisoldipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle. This leads to vasodilation, reduced peripheral vascular resistance, and decreased myocardial oxygen demand.
Initial: 5 mg orally once daily. Maintenance: 2.5–10 mg orally once daily. Maximum: 10 mg/day.
10-20 mg orally once daily; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life 2-5 hours in healthy adults; 7-12 hours in patients with hepatic impairment or advanced age
Terminal half-life of 24-50 hours, mean ~34 hours; extended in elderly and hepatic impairment, dose adjustment may be needed
Renal (approximately 70% as metabolites, <0.5% unchanged); fecal (approximately 10%)
Renal: 50-60% as metabolites, 10% as unchanged drug; Fecal: ~35%; Biliary: <5%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker